The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

(VAS): Visual Analogue Scale; (NRS): Numerical Rating Scale; (VRS): Verbal Rating Scales; (BP-EP): Breakthrough or intense Episodic Pain; (CI): Confidence Interval. CB participated in the design ...

Both trials met the primary endpoint of time-weighted sum of pain intensity difference on the numeric pain rating scale at the 48-hour mark versus placebo. The least squares mean difference after ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

This scale measures pain intensity on a 0 through 10 basis. Placebo patients reported a 1.98-point improvement in their pain intensity. Vertex is still planning to move suzetrigine into Phase 3 ...

NRS also showed higher reproducibility when measuring pain exacerbations (Cohen's K of 0.86 for NRS vs. 0.53 for VRS) while the reproducibility of the two scales was similar in evaluating ...